Review of the safety and efficacy of ustekinumab

  • E.J. S
  • S. K
  • 3

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Ustekinumab is a subcutaneously and intravenously administered fully human monoclonal immunoglobulin (IgG1) antibody targeting the interleukin (IL)-12/23 shared P40 subunit. The pivotal role of IL-12/23 inflammatory-mediated pathways is increasingly recognized in a plethora of immune-mediated inflammatory disorders including Crohngs disease, psoriasis, and multiple sclerosis. In a randomized controlled trial of ustekinumab in moderate-to-severe Crohngs disease, clinical response was achieved most notably in infliximab-experienced primary and secondary nonresponders and suboptimal responders. © The Author(s), 2010.

Author-supplied keywords

  • *Crohn disease/dt [Drug Therapy]
  • *ustekinumab/ae [Adverse Drug Reaction]
  • *ustekinumab/cr [Drug Concentration]
  • *ustekinumab/ct [Clinical Trial]
  • *ustekinumab/do [Drug Dose]
  • *ustekinumab/dt [Drug Therapy]
  • *ustekinumab/iv [Intravenous Drug Administration]
  • *ustekinumab/pd [Pharmacology]
  • *ustekinumab/pk [Pharmacokinetics]
  • *ustekinumab/sc [Subcutaneous Drug Administration]
  • C reactive protein/ec [Endogenous Compound]
  • abt 874
  • anxiety
  • arthralgia/si [Side Effect]
  • clinical effectiveness
  • clinical trial
  • disease exacerbation/si [Side Effect]
  • drug absorption
  • drug dose increase
  • drug efficacy
  • drug elimination
  • drug half life
  • drug safety
  • drug tolerability
  • drug treatment failure
  • gamma interferon/ec [Endogenous Compound]
  • headache/si [Side Effect]
  • human
  • human monoclonal antibody/dt [Drug Therapy]
  • infliximab/dt [Drug Therapy]
  • interleukin 12/ec [Endogenous Compound]
  • multiple sclerosis/dt [Drug Therapy]
  • nausea/si [Side Effect]
  • paraprotein/ec [Endogenous Compound]
  • phase 2 clinical trial
  • phase 3 clinical trial
  • placebo
  • priority journal
  • pruritus/si [Side Effect]
  • psoriasis/dt [Drug Therapy]
  • remission
  • respiratory tract infection/si [Side Effect]
  • review
  • rhinopharyngitis/si [Side Effect]
  • side effect/si [Side Effect]
  • treatment response

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Scherl E.J.

  • Kumar S.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free